COMPANY PROFILE

Nodality

Explore full profile

Biologically-informed clinical treatments for patients with cancer and autoimmune diseases

San Francisco, United StatesFounded 2003Biotech & Life Sciences

Valuation $50–100M Last recorded · 2010

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Nodality

Nodality, Inc. specializes in providing advanced human cell-based translational models to the pharmaceutical industry, focusing on disease, drug action, and patient-specific responses. Utilizing their proprietary Single Cell Network Profiling (SCNP) technology, a multiparametric flow cytometry platform, Nodality offers robust and reproducible models that address complex questions in drug discovery and development. The company serves drug developers and researchers, particularly in the fields of immuno-oncology and personalized medicine. Nodality's business model revolves around offering customized services and products that enhance pharmaceutical R&D, from early-stage discovery to late-stage development. Revenue is generated through service contracts, product sales, and collaborative partnerships with pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2003
Headquarters: San Francisco, United States
Employees: 2
Open positions: None listed
Dealroom signal: 52.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBT✓Debt	Aug 2011	$10M	—	Pfizer Ventures	—
DEBT✓Debt	Mar 2010	$2M	—	Kleiner Perkins	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Nodality website traffic

Latest recorded traffic for Nodality is 380 monthly website visits, up 153.3% over the last three months. Nodality's team grew 0% over the past year.

Latest monthly visits380 3-month web change+153.3% 1-year team growth0%

Monthly website visitsOct 2017–Apr 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATALTx TherapeuticsFirst-in-class precision oncology targeting immortal cancer cell pathways.	Houghton and Wyton, United Kingdom	Operational	—	$13M	$50M
MBMetri BioTherapeutics for endometrial diseases using 3D modeling	Boston, United States	Operational
KTKodiform TherapeuticsA drug discovery company with an initial focus on cancer	London, United Kingdom	Operational
SPSpliceorRNA trans-splicing gene therapies for aggressive cancers	Cambridge, United Kingdom	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
ONOncoLizeInjectable drug depots to treat tumors from the inside	Maastricht, Netherlands	Operational
MTMnemo TherapeuticsDeveloping powerful cell therapies that create accessible cures for solid tumors and blood cancers. EnfiniT platform, a groundbreaking drug discovery engine	Paris, France	Low Activity
ATAmbagon TherapeuticsBiotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment	Eindhoven, Netherlands	Operational